Lanoxin (Digoxin)

Digoxin exerts its effect by inhibiting the Na⁺/K⁺‑ATPase pump on cardiac cells. This inhibition raises intracellular sodium, which in turn reduces calcium extrusion via the sodium‑calcium exchanger. The resulting calcium buildup strengthens heart muscle contraction, and increased vagal tone prolongs AV‑node refractory period, slowing heart rate.

The exact dose of digoxin is individualized by the prescribing clinician. Factors such as the patient’s age, renal function, body weight, serum electrolyte levels, and target therapeutic range guide the initial and maintenance dosing, which is adjusted based on clinical response and serum drug concentrations.

Digoxin is classified as Pregnancy Category C, meaning risk cannot be ruled out. It may be used when the potential benefit justifies the potential fetal risk. Limited data suggest that digoxin passes into breast milk in small amounts; clinicians should weigh benefits against possible infant exposure.

To request Lanoxin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Compared with other inotropes such as milrinone or dobutamine, digoxin has a longer half‑life and provides both inotropic support and rate control. It does not increase myocardial oxygen consumption as markedly as catecholamine‑based agents, but its narrow therapeutic window requires careful monitoring for toxicity.

Lanoxin should be stored at 2‑8 °C in a refrigerator, protected from light. The vial must not be frozen or shaken vigorously. Prior to use, inspect the solution for particulate matter or discoloration and discard if any abnormalities are observed.

Lanoxin is supplied as an injectable solution for intravenous administration. It can be given as a slow IV bolus or diluted in compatible IV fluids for infusion, according to the prescribing clinician’s instructions and the patient’s clinical condition.

The most critical risks involve digoxin toxicity, which can manifest as life‑threatening cardiac arrhythmias, severe bradycardia, heart block, and hyperkalemia. Visual disturbances such as yellow‑green halos and gastrointestinal symptoms may also herald toxicity and require immediate medical evaluation.

Lanoxin is contraindicated in patients with ventricular fibrillation, advanced atrioventricular block without a pacemaker, and in those with known hypersensitivity to digoxin or any component of the formulation. Caution is also advised in patients with severe renal impairment or uncontrolled electrolyte disturbances.